BrevaRex

BrevaRex

A phase-II trial, activated murine monoclonal antibody developed for treating tumours expressing MUC-1—e.g., breast, prostate, pancreas, renal, lung and colorectal cancers.
References in periodicals archive ?
BrevaRex MAb targets the tumor associated antigen MUC1 and has successfully completed a Phase I safety and immunology study.
Ragupathy Madiyalakan, one of the founding executives of AltaRex, to the development of AltaRex's antibody directed immunotherapy program, which led to the discovery of OvaRex, Brevarex and Prostarex.
Additional findings for BrevaRex MAb (under development for multiple myeloma), GivaRex Mab (under development for gastrointestinal cancers), and ProstaRex MAb (under development for prostate cancer) illustrate the importance of using a foreign antibody that complexes with a circulating TAA.
The Compnay's most advanced product, OvaRex MAb for ovarian cancer, is in two potentially pivotal Phase IIb clinical trials, while BrevaRex MAb is in a Phase I study.
The company's most advanced product, OvaRex MAb for ovarian cancer, is in two potentially pivotal Phase IIb clinical trials, while BrevaRex MAb has recently entered a Phase I study.
Full browser ?